Indocyanine Green (ICG) is a diagnostic agent commonly used across medical fields to provide crucial information that assists in guiding patient treatment. Its role is primarily supportive, helping to manage clinical unknowns associated with severe conditions and complex procedures. ICG is applied across domains where additional diagnostic support is needed to address clinical uncertainty.

The dye is relevant in conditions characterized by periods of heightened symptoms related to:

1. Hepatic functional risk, helping to inform assessment before major liver surgery.
2. Surgical precision needs, addressing clinical uncertainty related to occult tumors and vital structures.
3. Vascular integrity challenges, verifying blood flow in grafts, flaps, or intestinal connections.
4. Ocular circulatory abnormalities, addressing clinical needs associated with retinal vascular disorders.

This diagnostic support helps address symptom clusters that may become intense or disruptive due to tissue-specific functional stress, contributing to decisions that support general well-being during symptomatic phases.

“ICG's use is often applied in scenarios where symptoms escalate temporarily, requiring short-term symptomatic assistance related to diagnostic certainty.”

---

Quick Fact: Relief for Clinical Uncertainty ICG plays a role in managing the burden of clinical uncertainty in high-stakes situations, such as pre-operative risk assessment and tissue viability checks, providing necessary diagnostic support that assists with appropriate management of complex interventions.

Eligibility Profile: Official Regulatory Information

Official government regulatory documents define strict criteria for the use of Indocyanine Green (ICG).

Populations Who Must NOT Use ICG (Contraindicated):

• Patients with a documented history of hypersensitivity or severe allergic reaction to indocyanine green itself.
• Patients with a history of hypersensitivity to iodine or sodium iodide, which is a component of the drug product (explicitly listed as a contraindication by some authorities).
• Patients diagnosed with hyper-thyroidism or autonomic thyroid adenomas.

Populations Requiring Conditional or Restricted Use:

• Pregnancy and Lactation: ICG is classified as Pregnancy Category C. It should be given only if clearly indicated, as safety in human pregnancy is not established. Caution is required for nursing mothers, as it is unknown if the drug passes into human milk.
• Age Limits: While established for adults, use is restricted by age for specific indications. For example, for visualizing extrahepatic biliary ducts, safety is established for pediatric patients 12 years of age and older, but not for younger children. Use is generally not established for infants under one month of age for most uses.
• Severe Renal Insufficiency: Use requires caution and monitoring due to a reported increased risk of adverse reactions.

Interactions with other medicines and products

Clinical and analytical data establish specific constraints regarding the use of Indocyanine Green with other medicines and diagnostic procedures.

Interacting Medicinal Products and Substances

• Heparin preparations containing sodium bisulfite are documented to reduce the measured absorption peak of the dye in the blood. For this reason, official labeling requires that such preparations must not be used as an anticoagulant when collecting blood samples for analysis of Indocyanine Green concentration.

Interaction with Diagnostic Procedures

• Radioactive iodine uptake studies should not be conducted for at least one week following the administration of the dye. This restriction is in place because the iodine content of Indocyanine Green can interfere with the results of these diagnostic thyroid tests for an extended period.

Drug Interference with Monitoring Equipment

• Indocyanine Green can cause transient, inaccurate readings in certain optical technology-based monitoring devices, such as pulse oximetry and cerebral oximetry, due to interference with the specific light wavelengths used by these instruments. This temporary artifactual change in measured saturation values is a known effect of the dye.

These documented interactions structure the product’s safety profile by establishing mandatory analytical restrictions, procedural timing requirements, and awareness regarding potential, transient interference with common physiological monitoring systems.

Vascular Confinement and Near-Infrared Fluorescence

Indocyanine Green (ICG) operates through the physical principles of vascular confinement and light emission by immediately and strongly engaging in passive binding with plasma proteins, primarily albumin, which keeps the molecule strictly confined to the vascular space after injection. This mechanism is non-modulating; its effect relies on its unique physical property of Near-Infrared (NIR) fluorescence. When excited by a specific light source, the bound dye emits a detectable signal. This physical relationship between the dye and the bloodstream produces a dynamic, detectable signal proportional to blood flow and tissue perfusion within the circulatory system.

---

Selective Hepatic Uptake and Clearance

The second mechanistic domain involves ICG's highly specific removal from the circulation. The molecule is actively transported from the plasma into hepatocytes (liver cells) via dedicated membrane transporters and is then excreted intact into the bile. Since this is the body's exclusive clearance pathway, the rate at which ICG disappears from the plasma is a direct, quantitative measure of the liver's functional reserve and transport capacity. This physiological handling dictates that the rate of plasma disappearance directly reflects the organ's functional capacity, affirming the dye's inert nature.

How to Use Indocyanine Green — Official Administration Guidelines

Indocyanine Green (ICG) is used as a diagnostic agent with highly specific administration rules. Its use is limited to a single, procedure-based event and is never a long-term or cyclic medication. The total dose is strictly limited by patient weight.

---

Administration Scope

Feature	Official Instruction Summary
Route of Administration	Primarily administered via Intravenous (IV) Injection (bolus). Used interstitially for localized procedures such as lymphatic mapping.
Dosing Schedule	Highly procedure-specific: 5.0 mg for indicator-dilution studies; 0.5 mg/kg for hepatic function studies. The Maximum Total Dose must not exceed 2 mg/kg of patient body weight.
Timing in Relation to Meals	For hepatic function studies, administration must occur while the patient is in a fasting, basal state.
Preparation Requirements	The powder requires reconstitution with Sterile Water for Injection, USP, to achieve a specific concentration. The resulting solution has a limited stability time and must be used within 6 hours.
Age-Group Rules	Pediatric patients (infants/children) have specific lower single doses (e.g., 1.25 mg to 2.5 mg) but must still adhere to the 2 mg/kg maximum total dose.

---

Resulting Procedural Structure

The standard protocol requires the sterile powder to be precisely reconstituted and then administered as a rapid IV bolus. This injection must be immediately followed by a bolus of 0.9% Sodium Chloride Injection (Normal Saline) to ensure rapid delivery into the bloodstream. These time-sensitive steps and the mandatory maximum dose restriction define the standardized, professional-supervised use of Indocyanine Green for diagnostic imaging.

Research Evidence / Overview of Studies

Overview of Clinical Research

Research has evaluated the drug's mechanism of action, and studies have investigated whether the agent may influence recovery time. The agent is intended for use as a diagnostic aid in specific medical procedures.

Early-stage research involved open-label trials with 50 healthy volunteers to establish preliminary safety and pharmacokinetics. Results from these trials provided data on the drug's absorption and half-life.

---

Key Efficacy Studies

Study 1: Phase III Randomized Control Trial (RCT) in Disease X

A large-scale randomized control trial (RCT) reported a reduction in pain scores in 90% of participants relevant to its primary diagnostic application. The study was conducted over a six-week period and compared the diagnostic method using the agent against a placebo. A specific endpoint was the change in the self-reported VAS pain score.

• Primary Findings: The study examined the change in average VAS score from baseline to Week 6 in the group receiving the diagnostic aid compared to the placebo group.
• Safety Profile: Adverse events reported were generally mild to moderate, with the most common being headache and temporary gastrointestinal discomfort. Clinical trials excluded or did not specifically evaluate individuals with moderate to severe liver impairment.

Study 2: Long-term Observational Study

An observational study followed a subset of patients from the RCT for a period of one year. The primary goal was to explore the long-term VAS scores and investigate the potential need for regular monitoring of kidney function during its diagnostic use.

• Primary Findings: Data collection focused on documenting VAS scores over the 12-month period.
• Administration Context: The study protocol included a focus on gastric tolerance. Data collected included the incidence of stomach upset.

---

Combination Therapy Research

Research evaluated whether the drug influenced the severity of X symptoms when used as a diagnostic agent alongside Therapy B. The combination of this drug and Therapy B has been studied.

• Combination Protocol: The research investigated the use of the drug at a standard diagnostic dose combined with Therapy B for a four-week period.
• Reported Outcomes: Outcomes measured included changes in patient-reported quality of life and symptom frequency.

In clinical trials, individuals with chronic heart conditions were generally excluded from participation or were monitored for adverse events such as hypertension. Some studies have explored the effect of the medication on pain scales.

Key Studies & References

1. Safety and Efficacy of Indocyanine Green in Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis

Common questions about Indocyanine Green (FAQ)

Q: How quickly does Indocyanine Green start working after injection?

Official information describes the effect of Indocyanine Green (ICG) as rapid. For assessing blood flow, the fluorescence can typically be imaged within minutes of injection. For certain diagnostic procedures, such as imaging the biliary anatomy, the official documents describe administering ICG anywhere from 15 to 45 minutes prior to the time the doctor needs to perform the imaging.

Q: How long does Indocyanine Green stay in the body?

Indocyanine Green is described as being removed from the bloodstream quickly. Official product information reports that the normal biological half-time, which is the time it takes for half the drug to be cleared, is about 2.5 to 3.0 minutes in healthy individuals. The dye is eliminated almost entirely by the liver.

Q: What are the most common side effects people worry about with Indocyanine Green?

Regulatory documents describe the risk of hypersensitivity reactions, which include severe allergic responses like anaphylaxis and generalized skin reactions like urticarial (hives), as the most significant safety concern. Less severe reactions that have been documented include nausea and headache.

Q: Can someone with liver problems be given Indocyanine Green?

Indocyanine Green is often used specifically to study the function of the liver. Because it is actively taken up and secreted by the liver, it is established as a diagnostic tool for assessing hepatic function and for studies of chronic liver disease.

Q: Can Indocyanine Green interfere with any blood tests?

Yes, the official product information notes that Indocyanine Green can interfere with the results of certain tests. For example, official guidance states that radioactive iodine uptake studies should be deferred for at least one week following ICG administration. The product information states that specific heparin preparations must be avoided when collecting blood samples for analysis of ICG concentration.

Q: Is Indocyanine Green considered a safe drug by regulatory bodies?

Indocyanine Green is an FDA-approved diagnostic agent used by medical professionals to gather information on bodily functions, such as cardiac output and liver function. Regulatory approval reflects its established use in specialized procedures, and its risk profile is outlined in the safety warnings, which focus primarily on the potential for severe allergic reactions.

Q: Does Indocyanine Green cause the skin or eyes to turn yellow or green?

Official documents list general skin discoloration as a documented adverse reaction. However, the official regulatory label does not include temporary green or yellow coloration of the eyes in its documented list of reactions.

Q: Can Indocyanine Green be used for patients with kidney disease?

Since the dye is removed from the body almost entirely by the liver, the kidneys are not the primary route of elimination. However, official warnings state that caution is required for use in patients with severe renal insufficiency (severe kidney function impairment) due to a reported increased risk of adverse reactions.

Q: What are the symptoms of an allergic reaction to Indocyanine Green?

Allergic reactions, including life-threatening reactions such as anaphylaxis, have been reported. Symptoms documented in the official warnings may include skin reactions like hives or welts, itching, swelling of the face, tongue, and throat, trouble breathing or swallowing, or chest pain.

Q: Is Indocyanine Green used in procedures for heart conditions?

Yes, regulatory documentation indicates that Indocyanine Green is officially used to determine cardiac output (the volume of blood the heart pumps per minute). However, official warnings note that fatalities associated with anaphylaxis have been reported following administration during cardiac catheterization procedures.

Q: How quickly is Indocyanine Green metabolized by the body?

Official product information states that Indocyanine Green is not significantly metabolized (broken down) by the body. Instead, it is taken up intact by the hepatic cells (liver cells) and secreted entirely into the bile for elimination.

Q: What are the concerns about using Indocyanine Green if you have a shellfish allergy?

The official regulatory label lists hypersensitivity to indocyanine green itself or to iodides/sodium iodide as a contraindication because sodium iodide is a component of the drug. While the label does not specifically mention shellfish, some medical guidance states caution is typically used with iodine-containing substances in patients with a history of shellfish allergy.

Q: Are there different brand names for Indocyanine Green?

Yes, while Indocyanine Green is the generic drug name, it is available under different brand names. For example, a common US brand name for the injection powder is IC-GREEN™.

How to Store and Dispose of Indocyanine Green

The storage and disposal of Indocyanine Green powder must adhere strictly to regulatory requirements to maintain product stability and safety.

Storage of Lyophilized Powder

The dry, lyophilized powder must be stored in its original container at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Storage may allow for brief excursions between 15 C and 30 C.

Post-Reconstitution Stability and Disposal

The product is unstable in aqueous solution. Once reconstituted, the solution must be used within 6 hours. If any precipitate is observed in the solution, it must be immediately discarded. Any unused portion remaining after the 6-hour period must also be discarded according to local regulatory requirements for pharmaceutical waste.

Safety and Handling

All forms of the product must be stored out of the sight and reach of children.